

R H I N O M E D

UPDATE ON AGM AND IMPENDING BOARD CHANGE

20 October 2023: Melbourne, Australia.

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, wishes to provide an update to the Notice of Annual General Meeting that was lodged on the ASX on 18 October 2023.

Resolution 3 of the Notice of Annual General Meeting provided for the re-election of Mr. Ryan McIntyre, who was anticipated to be appointed as a Non-Executive Director to the Board of Directors prior to the meeting on 17 November 2023.

Resolution 3 is to be withdrawn and will not be put to a vote at the Annual General Meeting.

Rhinomed's Chairman Mr. Ron Dewhurst said, "Ryan McIntyre's existing commitments have recently changed and therefore is unable to commit the time at present required for this appointment and will reevaluate his availability at a later point in time."

This report has been authorised for release to the market by the Board.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.